Therapies for Parkinson’s disease and the gut microbiome: evidence for bidirectional connection

The gut brain axis (GBA), a bidirectional communication pathway has often been linked to health and disease, and gut microbiota (GM), a key component of this pathway shown to be altered in Parkinson’s disease (PD), are suggested to contribute to the pathogenesis of PD. There are few studies that report the impact of oral medication therapy on GM, however, there are even fewer studies that discuss the impact of other treatments such as device assisted therapies (DAT) including deep brain stimulation (DBS), levodopa-carbidopa intestinal gel infusion (LCIG) and photobiomodulation (PBM) and how these might impact GM. Here, we review the literature and summarize findings of the potential contributions of GM to the heterogenous clinical response to pharmaceutical therapies among individuals with PD. We also discuss the potential interactions between the GM and DATs such as DBS and LCIG and present evidence for alterations in GM in response to DATs. Given the complexity and highly individual nature of the GM of patients with PD and the potential influence that other external factors such as diet, lifestyle, medications, stage of the disease and other comorbidities, further investigations into the response of GM to therapies are worthy of future study in prospective, controlled trials as well as medication naïve individuals. Such detailed studies will help us further comprehend the relationship between GM in PD patients, and will help investigate the potential of targeting GM associated changes as a treatment avenue for PD.

[1]  H. Dupont,et al.  Fecal microbiota transplantation in Parkinson's disease—A randomized repeat-dose, placebo-controlled clinical pilot study , 2023, Frontiers in Neurology.

[2]  Chen Liang,et al.  Vagus Nerve and Underlying Impact on the Gut Microbiota-Brain Axis in Behavior and Neurodegenerative Diseases , 2022, Journal of inflammation research.

[3]  Shamsher Singh,et al.  Microbiota- Brain-Gut-Axis Relevance to Parkinson's Disease: Potential Therapeutic Effects of Probiotics. , 2022, Current pharmaceutical design.

[4]  B. Bonaz Anti‐inflammatory effects of vagal nerve stimulation with a special attention to intestinal barrier dysfunction , 2022, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[5]  L. Dicks Gut Bacteria and Neurotransmitters , 2022, Microorganisms.

[6]  A. Lang,et al.  The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic , 2022, Nature Reviews Neurology.

[7]  Ryan L. Davis,et al.  The Gut Microbiome in Parkinson’s Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies , 2022, Frontiers in Aging Neuroscience.

[8]  Y.-C. Hsieh,et al.  A Pilot Study Exploring the Association of Entacapone, Gut Microbiota, and the Subsequent Side Effects in Patients With Parkinson’s Disease , 2022, Frontiers in Cellular and Infection Microbiology.

[9]  Madalina Bucur,et al.  Deep Brain Stimulation in Parkinson Disease: A Meta-analysis of the Long-term Neuropsychological Outcomes , 2022, Neuropsychology Review.

[10]  M. Farrer,et al.  The Gut–Brain Axis and Its Relation to Parkinson’s Disease: A Review , 2022, Frontiers in Aging Neuroscience.

[11]  B. Bicknell,et al.  Microbiome Changes in Humans with Parkinson’s Disease after Photobiomodulation Therapy: A Retrospective Study , 2022, Journal of personalized medicine.

[12]  B. Ellingson,et al.  Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement , 2021, Microbiome.

[13]  Y. Zlotnik,et al.  Fecal microbiota transplant as a potential treatment for Parkinson's disease – A case series , 2021, Clinical Neurology and Neurosurgery.

[14]  B. Popescu,et al.  Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson’s Disease , 2021, Frontiers in Neuroscience.

[15]  C. Sue,et al.  The impact of device-assisted therapies on the gut microbiome in Parkinson’s disease , 2021, Journal of Neurology.

[16]  J. Mitrofanis,et al.  Improvements in clinical signs of Parkinson’s disease using photobiomodulation: a prospective proof-of-concept study , 2021, BMC Neurology.

[17]  K. Chaudhuri,et al.  Gastrointestinal dysfunction in Parkinson’s disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation , 2021, Journal of Neurology.

[18]  B. Gao,et al.  Association of Parkinson’s Disease With Microbes and Microbiological Therapy , 2021, Frontiers in Cellular and Infection Microbiology.

[19]  Kara M. Smith,et al.  Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease , 2021, Frontiers in Neurology.

[20]  Li-juan Xu,et al.  Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation , 2021, Microbial Cell Factories.

[21]  C. Colosimo,et al.  Device-aided therapies for advanced Parkinson disease: insights from an international survey , 2021, Neurological Sciences.

[22]  L. Lopiano,et al.  Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa‐carbidopa intrajejunal gel , 2020, European journal of neurology.

[23]  B. Strukelj,et al.  The Influence of Probiotics on the Firmicutes/Bacteroidetes Ratio in the Treatment of Obesity and Inflammatory Bowel disease , 2020, Microorganisms.

[24]  Xin-tong Zhang,et al.  The influence of the gut microbiota on the bioavailability of oral drugs , 2020, Acta pharmaceutica Sinica. B.

[25]  P. Calabresi,et al.  Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities , 2020, Movement disorders : official journal of the Movement Disorder Society.

[26]  P. Marin,et al.  The 5-HT6 receptor interactome: New insight in receptor signaling and its impact on brain physiology and pathologies , 2020, Neuropharmacology.

[27]  Daniel M. Johnstone,et al.  Elucidating the time course of the transcriptomic response to photobiomodulation through gene co-expression analysis. , 2020, Journal of photochemistry and photobiology. B, Biology.

[28]  F. Magne,et al.  The Firmicutes/Bacteroidetes Ratio: A Relevant Marker of Gut Dysbiosis in Obese Patients? , 2020, Nutrients.

[29]  Michael R Hamblin,et al.  Photobiomodulation for Parkinson’s Disease in Animal Models: A Systematic Review , 2020, Biomolecules.

[30]  A. Keshavarzian,et al.  Gut bacterial deamination of residual levodopa medication for Parkinson’s disease , 2020, BMC Biology.

[31]  A. Kurilshikov,et al.  Impact of commonly used drugs on the composition and metabolic function of the gut microbiota , 2020, Nature Communications.

[32]  E. Mayer,et al.  Gut Microbiome and Modulation of CNS Function. , 2019, Comprehensive Physiology.

[33]  A. Patterson,et al.  The gut microbiome: an orchestrator of xenobiotic metabolism , 2019, Acta pharmaceutica Sinica. B.

[34]  M. Kohl,et al.  Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota , 2019, npj Parkinson's Disease.

[35]  A. Keshavarzian,et al.  Gut Vibes in Parkinson's Disease: The Microbiota‐Gut‐Brain Axis , 2019, Movement disorders clinical practice.

[36]  F. Scheperjans,et al.  Increasing Comparability and Utility of Gut Microbiome Studies in Parkinson’s Disease: A Systematic Review , 2019, Journal of Parkinson's disease.

[37]  A. Lang,et al.  Parkinson's disease in the Western Pacific Region , 2019, The Lancet Neurology.

[38]  W. Poewe,et al.  Apomorphine for Parkinson’s Disease: Efficacy and Safety of Current and New Formulations , 2019, CNS Drugs.

[39]  Daniel M. Johnstone,et al.  Remote photobiomodulation: an emerging strategy for neuroprotection , 2019, Neural regeneration research.

[40]  E. Hsiao,et al.  A novel pathway for microbial metabolism of levodopa , 2019, Nature Medicine.

[41]  A. Lucia,et al.  Photobiomodulation in Parkinson's disease: A randomized controlled trial , 2019, Brain Stimulation.

[42]  N. Bray The microbiota–gut–brain axis , 2019 .

[43]  Elizabeth N. Bess,et al.  Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism , 2019, Science.

[44]  E. Pekkonen,et al.  Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression , 2019, EBioMedicine.

[45]  T. Dinan,et al.  Gut Microbe to Brain Signaling: What Happens in Vagus… , 2019, Neuron.

[46]  Daniel M. Johnstone,et al.  Pre-conditioning with Remote Photobiomodulation Modulates the Brain Transcriptome and Protects Against MPTP Insult in Mice , 2019, Neuroscience.

[47]  A. Keshavarzian,et al.  Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease , 2019, Nature Communications.

[48]  E. Dardiotis,et al.  H. pylori and Parkinson’s disease: Meta-analyses including clinical severity , 2018, Clinical Neurology and Neurosurgery.

[49]  Laurel A. Doherty,et al.  Effects of Psychological, Environmental and Physical Stressors on the Gut Microbiota , 2018, Front. Microbiol..

[50]  P. Borghammer Is constipation in Parkinson's disease caused by gut or brain pathology? , 2018, Parkinsonism & related disorders.

[51]  Daniel M. Johnstone,et al.  Photobiomodulation of the microbiome: implications for metabolic and inflammatory diseases , 2018, Lasers in medical science.

[52]  Hongwei Zhou,et al.  Gut microbiota in patients with Parkinson's disease in southern China. , 2018, Parkinsonism & related disorders.

[53]  L. McCullough,et al.  Age‐related changes in the gut microbiota influence systemic inflammation and stroke outcome , 2018, Annals of neurology.

[54]  E. Disbrow,et al.  Stomaching the Possibility of a Pathogenic Role for Helicobacter pylori in Parkinson’s Disease , 2018, Journal of Parkinson's disease.

[55]  F. Bäckhed,et al.  Gut microbiota regulates maturation of the adult enteric nervous system via enteric serotonin networks , 2018, Proceedings of the National Academy of Sciences.

[56]  V. Fung,et al.  Long‐term safety and efficacy of levodopa‐carbidopa intestinal gel in advanced Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.

[57]  U. Dillmann,et al.  Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson's disease. , 2018, Parkinsonism & related disorders.

[58]  S. Factor,et al.  Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease , 2018, Movement disorders : official journal of the Movement Disorder Society.

[59]  Michael R Hamblin,et al.  Mechanisms and Mitochondrial Redox Signaling in Photobiomodulation , 2018, Photochemistry and photobiology.

[60]  A. Heintz‐Buschart,et al.  The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder , 2017, Movement disorders : official journal of the Movement Disorder Society.

[61]  T. Scheper,et al.  Immune responses against Helicobacter pylori-specific antigens differentiate relapsing remitting from secondary progressive multiple sclerosis , 2017, Scientific Reports.

[62]  J. Stone,et al.  Remote tissue conditioning — An emerging approach for inducing body-wide protection against diseases of ageing , 2017, Ageing Research Reviews.

[63]  J. Álvarez-Sabín,et al.  Long‐term safety and effectiveness of levodopa‐carbidopa intestinal gel infusion , 2017, Brain and behavior.

[64]  Joyce K Y Tse Gut Microbiota, Nitric Oxide, and Microglia as Prerequisites for Neurodegenerative Disorders. , 2017, ACS chemical neuroscience.

[65]  Suneil K. Kalia,et al.  Deep brain stimulation for Parkinson's disease: meta-analysis of results of randomized trials at varying lengths of follow-up. , 2017, Journal of neurosurgery.

[66]  James T. Morton,et al.  Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome , 2017, Movement disorders : official journal of the Movement Disorder Society.

[67]  Luis Pedro Coelho,et al.  Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson’s disease patients , 2017, Genome Medicine.

[68]  V. Govorun,et al.  Analysis of Gut Microbiota in Patients with Parkinson’s Disease , 2017, Bulletin of Experimental Biology and Medicine.

[69]  Wei Li,et al.  Structural changes of gut microbiota in Parkinson’s disease and its correlation with clinical features , 2017, Science China Life Sciences.

[70]  K. Krogh,et al.  Constipation in parkinson's disease: Subjective symptoms, objective markers, and new perspectives , 2017, Movement disorders : official journal of the Movement Disorder Society.

[71]  K. Fassbender,et al.  Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. , 2016, Parkinsonism & related disorders.

[72]  E. Cereda,et al.  Probiotics and prebiotic fiber for constipation associated with Parkinson disease , 2016, Neurology.

[73]  Zhi-hua Wang,et al.  Prevalence of small intestinal bacterial overgrowth in Chinese patients with Parkinson’s disease , 2016, Journal of Neural Transmission.

[74]  B. Ahmer,et al.  The commensal microbiota exacerbate infectious colitis in stressor-exposed mice , 2016, Brain, Behavior, and Immunity.

[75]  M. Dichgans,et al.  Microbiota Dysbiosis Controls the Neuroinflammatory Response after Stroke , 2016, The Journal of Neuroscience.

[76]  V. Sperandio,et al.  Interactions between the microbiota and pathogenic bacteria in the gut , 2016, Nature.

[77]  M. Eisenstein Microbiome: Bacterial broadband , 2016, Nature.

[78]  D. Kasper,et al.  How colonization by microbiota in early life shapes the immune system , 2016, Science.

[79]  V. Fung,et al.  Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson’s disease , 2016, Journal of Clinical Neuroscience.

[80]  R. Ley Gut microbiota in 2015: Prevotella in the gut: choose carefully , 2016, Nature Reviews Gastroenterology &Hepatology.

[81]  Daniel M. Johnstone,et al.  Turning On Lights to Stop Neurodegeneration: The Potential of Near Infrared Light Therapy in Alzheimer's and Parkinson's Disease , 2016, Front. Neurosci..

[82]  Wei Jia,et al.  The influence of gut microbiota on drug metabolism and toxicity , 2016, Expert opinion on drug metabolism & toxicology.

[83]  K. Ohno,et al.  Intestinal Dysbiosis and Lowered Serum Lipopolysaccharide-Binding Protein in Parkinson’s Disease , 2015, PloS one.

[84]  B. Bonaz,et al.  Brain-gut-microbiota axis in Parkinson's disease. , 2015, World journal of gastroenterology.

[85]  G. Demaagd,et al.  Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis. , 2015, P & T : a peer-reviewed journal for formulary management.

[86]  C. Fukaya,et al.  Deep Brain Stimulation for Parkinson’s Disease: Recent Trends and Future Direction , 2015, Neurologia medico-chirurgica.

[87]  J. Sonnenburg,et al.  Gut microbes promote colonic serotonin production through an effect of short‐chain fatty acids on enterochromaffin cells , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[88]  M. Carabotti,et al.  The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems , 2015, Annals of gastroenterology.

[89]  M. Heymann,et al.  Structural alterations of the intestinal epithelial barrier in Parkinson’s disease , 2015, Acta neuropathologica communications.

[90]  E. Pekkonen,et al.  Gut microbiota are related to Parkinson's disease and clinical phenotype , 2015, Movement disorders : official journal of the Movement Disorder Society.

[91]  A. Lang,et al.  Helicobacter pylori infection is associated with worse severity of Parkinson's disease. , 2015, Parkinsonism & related disorders.

[92]  Daniel M. Johnstone,et al.  Targeting the body to protect the brain: inducing neuroprotection with remotely-applied near infrared light , 2015, Neural regeneration research.

[93]  R. Wu,et al.  Risk of Parkinson's disease following severe constipation: a nationwide population-based cohort study. , 2014, Parkinsonism & related disorders.

[94]  H. Tan,et al.  Eradication of Helicobacter pylori Infection Improves Levodopa Action, Clinical Symptoms and Quality of Life in Patients with Parkinson's Disease , 2014, PloS one.

[95]  M. Hallett,et al.  Drooling in Parkinson's disease: a review. , 2014, Parkinsonism & related disorders.

[96]  K. Kieburtz,et al.  Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study , 2014, The Lancet Neurology.

[97]  R. Dobbs,et al.  Significantly higher frequency of Helicobacter suis in patients with idiopathic parkinsonism than in control patients , 2013, Alimentary pharmacology & therapeutics.

[98]  M. Icaza-Chávez,et al.  Gut microbiota in health and disease , 2013 .

[99]  R. Klopfleisch,et al.  Commensal Akkermansia muciniphila Exacerbates Gut Inflammation in Salmonella Typhimurium-Infected Gnotobiotic Mice , 2013, PloS one.

[100]  Barbara M. Bakker,et al.  The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism , 2013, Journal of Lipid Research.

[101]  A. Gasbarrini,et al.  The role of small intestinal bacterial overgrowth in Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[102]  E. Verdu,et al.  Modulation of intestinal barrier by intestinal microbiota: pathological and therapeutic implications. , 2013, Pharmacological research.

[103]  D. Devos,et al.  Colonic inflammation in Parkinson's disease , 2013, Neurobiology of Disease.

[104]  R. Sakakibara,et al.  Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease , 2012, Journal of the Neurological Sciences.

[105]  D. Nyholm,et al.  Levodopa/carbidopa intestinal gel infusion long‐term therapy in advanced Parkinson’s disease , 2012, European journal of neurology.

[106]  E. Quigley,et al.  Gastroparesis and Parkinson's disease: a systematic review. , 2012, Parkinsonism & related disorders.

[107]  B. Ritz,et al.  Treatment for Helicobacter pylori infection and risk of parkinson’s disease in Denmark , 2012, European journal of neurology.

[108]  Antonio Daniele,et al.  Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation , 2012, The Lancet Neurology.

[109]  O. Suchowersky,et al.  Increased Intestinal Permeability and Parkinson Disease Patients: Chicken or Egg? , 2012, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[110]  Jeffrey H. Kordower,et al.  Increased Intestinal Permeability Correlates with Sigmoid Mucosa alpha-Synuclein Staining and Endotoxin Exposure Markers in Early Parkinson's Disease , 2011, PloS one.

[111]  Olli Simell,et al.  Gut Microbiome Metagenomics Analysis Suggests a Functional Model for the Development of Autoimmunity for Type 1 Diabetes , 2011, PloS one.

[112]  K. Krogh Gastrointestinal Dysfunction in Parkinson’s Disease , 2011 .

[113]  B. Bloem,et al.  Pathophysiology of diurnal drooling in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[114]  Senna Prune Diet Constipation in Parkinson's disease , 2011, Annals of Indian Academy of Neurology.

[115]  A. Gasbarrini,et al.  Prevalence of Small Intestinal Bacterial Overgrowth in Parkinson's Disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[116]  N. Van Rooijen,et al.  Ulcerative colitis exacerbates lipopolysaccharide‐induced damage to the nigral dopaminergic system: potential risk factor in Parkinson`s disease , 2010, Journal of neurochemistry.

[117]  R. Dobbs,et al.  Differential Effect of Helicobacter pylori Eradication on Time-Trends in Brady/Hypokinesia and Rigidity in Idiopathic Parkinsonism , 2010, Helicobacter.

[118]  S. Mazmanian,et al.  The gut microbiota shapes intestinal immune responses during health and disease , 2009, Nature Reviews Immunology.

[119]  E. Mayer,et al.  Principles and clinical implications of the brain–gut–enteric microbiota axis , 2009, Nature Reviews Gastroenterology &Hepatology.

[120]  D. Nicaretta,et al.  Scintigraphic analysis of the parotid glands in patients with sialorrhea and Parkinson's disease. , 2008, Parkinsonism & related disorders.

[121]  D. Relman,et al.  An ecological and evolutionary perspective on human–microbe mutualism and disease , 2007, Nature.

[122]  P. Turnbaugh,et al.  Microbial ecology: Human gut microbes associated with obesity , 2006, Nature.

[123]  Mitchell J Barnett,et al.  Anticholinergic medications in community-dwelling older veterans: prevalence of anticholinergic symptoms, symptom burden, and adverse drug events. , 2006, The American journal of geriatric pharmacotherapy.

[124]  E. Purdom,et al.  Diversity of the Human Intestinal Microbial Flora , 2005, Science.

[125]  F. Bäckhed,et al.  Host-Bacterial Mutualism in the Human Intestine , 2005, Science.

[126]  H. Teräväinen,et al.  Clinical advantages of COMT inhibition with entacapone – a review , 2004, Journal of Neural Transmission.

[127]  C. Tanner,et al.  Frequency of bowel movements and the future risk of Parkinson’s disease , 2001, Neurology.

[128]  P. Odin,et al.  Apomorphine in the Treatment of Parkinson's Disease , 2001, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.

[129]  S. Kaakkola Clinical Pharmacology, Therapeutic Use and Potential of COMT Inhibitors in Parkinson’s Disease , 2000, Drugs.

[130]  A. Benabid,et al.  Thalamic, subthalamic nucleus and internal pallidum stimulation in Parkinson’s disease , 1999, Journal of Neurology.

[131]  M. Gershon The enteric nervous system: a second brain. , 1999, Hospital practice.

[132]  R. Dobbs,et al.  Parkinsonism: siblings share Helicobacter pylori seropositivity and facets of syndrome , 1999, Acta neurologica Scandinavica.

[133]  M. M. Benjamin,et al.  Acid tolerance of enterohemorrhagic Escherichia coli , 1995, Applied and environmental microbiology.

[134]  M. Hallett,et al.  Resetting of essential tremor and postural tremor in Parkinson's disease with transcranial magnetic stimulation , 1994, Muscle & nerve.

[135]  M. Hallett,et al.  Abnormal facilitation of the response to transcranial magnetic stimulation in patients with Parkinson's disease , 1994, Neurology.

[136]  E. Montgomery Pharmacokinetics and pharmacodynamics of levodopa , 1992, Neurology.

[137]  A. Benabid,et al.  Subcutaneous apomorphine in Parkinson's disease. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[138]  K. Chaudhuri,et al.  SUBCUTANEOUS APOMORPHINE FOR ON-OFF OSCILLATIONS IN PARKINSON'S DISEASE , 1988, The Lancet.

[139]  A. Lees,et al.  SUBCUTANEOUS APOMORPHINE IN PARKINSONIAN ON-OFF OSCILLATIONS , 1988, The Lancet.

[140]  A. C. Hamdan,et al.  Stroop Test for Parkinson's Disease with Deep Brain Stimulation: A Systematic Review. , 2022, Innovations in clinical neuroscience.

[141]  S. V. van Kessel,et al.  Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats , 2021, SSRN Electronic Journal.

[142]  C. Adler,et al.  Weight Loss in Parkinson's Disease: No Evidence for Role of Small Intestinal Bacterial Overgrowth. , 2018, Journal of Parkinson's disease.

[143]  A. Mangalam,et al.  The “Gut Feeling”: Breaking Down the Role of Gut Microbiome in Multiple Sclerosis , 2017, Neurotherapeutics.

[144]  J. Bienenstock,et al.  Vagal pathways for microbiome-brain-gut axis communication. , 2014, Advances in experimental medicine and biology.

[145]  D. Nyholm,et al.  Continuous Drug Delivery in Parkinson’s Disease , 2013, CNS Drugs.

[146]  M. Gelabert-González,et al.  [Deep brain stimulation in Parkinson's disease]. , 2013, Revista de neurologia.

[147]  D. Salat,et al.  Levodopa in the treatment of Parkinson's disease: current status and new developments. , 2013, Journal of Parkinson's disease.

[148]  L. Brandt,et al.  Should We Standardize the 1,700-Year-Old Fecal Microbiota Transplantation? , 2012, The American Journal of Gastroenterology.

[149]  N. Talley Medical records documentation of constipation preceding Parkinson disease: A case-control study , 2010 .

[150]  A. Neish,et al.  REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY Microbes in Gastrointestinal Health and Disease , 2009 .

[151]  Y Nakamura,et al.  [Problems of long-term levodopa therapy in Parkinson's disease]. , 1997, Nihon rinsho. Japanese journal of clinical medicine.

[152]  E. Quigley,et al.  Gastrointestinal symptoms in Parkinson's disease , 1991, Movement disorders : official journal of the Movement Disorder Society.